Mechanistic Study and Therapeutic Strategy of HDAC6 Regulates EGFR Signaling in Hepatocellular Carcinoma
碩士 === 輔英科技大學 === 醫學檢驗生物技術系碩士班 === 102 === In Taiwan, hepatocellular carcinoma (HCC) is the second most common cause of cancer death and causes more than 7,500 deaths each year. Nevertheless, approximately 75% of patients with HCC have advanced unresectable diseases upon presentation. Alterations of...
Main Authors: | Hong-Ying Dai, 戴宏穎 |
---|---|
Other Authors: | Yao-Tsung Yeh |
Format: | Others |
Language: | zh-TW |
Published: |
2014
|
Online Access: | http://ndltd.ncl.edu.tw/handle/19778475173548538156 |
Similar Items
-
Predisposition to Apoptosis in Hepatocellular Carcinoma: From Mechanistic Insights to Therapeutic Strategies
by: Jens U. Marquardt, et al.
Published: (2019-12-01) -
“Complimenting the Complement”: Mechanistic Insights and Opportunities for Therapeutics in Hepatocellular Carcinoma
by: Astha Malik, et al.
Published: (2021-02-01) -
Mechanistic Investigation on the Regulation of FABP1 by the IL-6/miR-603 Signaling in the Pathogenesis of Hepatocellular Carcinoma
by: Ye-xin Lin, et al.
Published: (2021-01-01) -
Regulation of the expression of ADAMTS1 and EGFR by HDAC inhibitors
by: Chia-Wei Chou, et al.
Published: (2010) -
Synergistic efficacy of combined EGFR and HDAC inhibitors overcomes tolerance to EGFR monotherapy in salivary mucoepidermoid carcinoma
by: Amelio, A.L, et al.
Published: (2021)